GlobeNewswire

Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy

Share

ORION CORPORATION                 PRESS RELEASE                8 JUNE 2021         AT 8.00 a.m. EEST

Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy

Orion Corporation and the Finnish Red Cross Blood Service have concluded an agreement on research collaboration with the aim of developing chimeric antigen receptor (CAR) T-cell therapy.

Cancer immunotherapies, with CAR T-cell therapy as one form of therapy, have introduced entirely new possibilities for cancer treatment. In CAR T-cell therapy, the patient's own white blood cells are genetically modified to attack the cancer and kill it. CAR T-cells are currently used to treat certain haematological cancers.

The first T-cell therapies received marketing authorisation in the USA in 2017 and in Finland in 2019 for the treatment of recurrent acute lymphocytic leukaemia and B-cell lymphoma. Despite the good treatment results, development needs have been identified in CAR T-cell therapies, which is why research related to CAR-T cell therapy is being pursued.

The Blood Service has considerable experience in cell research, in the supply of cord blood and stem cell grafts classified as tissue products, and in the preparation of ATMP cell products classified as medicinal products. The Blood Service also has expertise and the necessary clean rooms for the research and high-quality production of therapeutic cells.

Orion has a solid research infrastructure and has introduced several proprietary drugs to the market in different therapy areas. Orion's oncology therapy area researches and develops novel proprietary drugs for the treatment of cancer. In recent years, Orion has expanded its research activities to include immuno-oncology therapies.

New possibilities for cancer treatment

The research collaboration is based on new innovations to improve the structure of the CAR T-cell product. Matti Korhonen, Senior Medical Officer, who leads the research at the Blood Service, believes that the collaboration offers a great opportunity to develop new cell therapy products for patient care. According to Oliver Cooper, Ph.D., director of Discovery Sciences at Orion’s R&D, Orion’s drug development expertise will provide the necessary momentum for this project.

“Targeted immunotherapy has opened up entirely new possibilities for the treatment of cancer, and it is important to advance this development in Finland, too. I also believe that as a result of the development work, more and more patients will be able to benefit from this effective treatment,” says Matti Korhonen

Project managers Satu Juhila from Orion and Jan Koski from the Blood Service say that the collaboration has got off to a good start: “Both parties are very enthusiastic regarding the opportunities of the collaboration and about advancing the development of cell therapy in Finland. We believe that the collaboration will provide plenty of new opportunities for the development of cell therapy products.”

Finnish Red Cross Blood Service
The Finnish Red Cross Blood Service is the nationwide blood service provider in Finland. Its services comprise recruiting blood donors, organising blood donation, collecting blood and testing the donated blood. It is also responsible for producing and storing blood products and delivering them to hospitals. The Finnish Red Cross Blood Service is also responsible for supplying stem cell transplants, the HLA typing of organ and stem cell transplants and various laboratory testing related to blood. The Blood Service’s Cell Production Centre develops and produces experimental cell therapy products for the treatment of patients. The Finnish Red Cross Blood Service conducts scientific research related to its field. More detailed information is available in the Blood Service annual report 2020.

Further information:

Orion Corporation:
Outi Vaarala
Senior Vice President, Research and Development, Orion Corporation
Tel. +358 10 426 3472
outi.vaarala@orionpharma.com

Contact person for the media:

Terhi Ormio
Vice President, Communications, Orion Corporation
Tel. +358 50 966 4646
terhi.ormio@orion.fi

Finnish Red Cross, Blood Service:
Matti Korhonen, Senior Medical Officer
Finnish Red Cross, Blood Service
Tel. +358 50 396 9450
matti.korhonen@veripalvelu.fi

Contact person for the media:
Willy Toiviainen, Director of Communications and Human Resources
Finnish Red Cross, Blood Service
Tel. +358 40 523 7451
willy.toiviainen@veripalvelu.fi

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi/en

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million, and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS15.6.2021 11:30:00 CEST | Press release

AuctionAuction resultsAuction date2021-06-15Maturity2024Tendered volume, SEK mln1000 +/- 1000Offered volume, SEK mln137Volume bought, SEK mln137Number of bids3Number of accepted bids3 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln0000Volume bought, SEK mln0000Number of bids0000Number of accepted bids0000Average DM----Lowest accepted DM----Highest DM----Accepted at lowest DM---- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln013070Volume bought, SEK mln013070Number of bids0210Number of accepted bids0210Average DM--5-2-Lowest accepted DM--5-2-Highest DM--5-2-Accepted at lowest DM-100.00%100.00%-

Karolinska Development’s portfolio company Modus Therapeutics and Imperial College London to conduct clinical study of sevuparin in severe malaria15.6.2021 11:24:44 CEST | Press release

STOCKHOLM, SWEDEN – June 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has entered into a collaboration agreement with Imperial College London to evaluate the effect of its drug candidate sevuparin in patients with severe malaria. Sevuparin is currently being developed in the indication sepsis/septic shock, a condition that bears resemblance to the systemic inflammatory reaction that occurs in connection with severe malaria infection. Malaria causes more than 400,000 deaths per year and the need for new and effective drugs is therefore great. Severe malaria continues to be a medical challenge in several parts of the world. The disease often affects children and the need for effective drugs is great as malaria can induce a systemic inflammatory reaction leading to multi-organ failure, a reaction similar to that seen in sepsis/septic shock. The purpose of the collaboration announced today is to conduct a clinica

Karolinska Developments portföljbolag Modus Therapeutics och Imperial College London planerar klinisk studie av sevuparin mot svår malaria15.6.2021 11:24:44 CEST | Pressemelding

STOCKHOLM, SVERIGE 15 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics och Imperial College London har ingått ett samarbetsavtal i syfte att utvärdera effekten av bolagets läkemedelskandidat sevuparin i patienter med svår malaria. Sevuparin utvecklas sedan tidigare inom indikationen sepsis/septisk chock, ett tillstånd som bär vissa likheter med den systemiska inflammationsreaktion som uppstår i samband med svår malariainfektion. Malaria orsakar fler än 400 000 dödsfall per år och behovet av nya och effektiva läkemedel är därför stort. Svår malaria utgör fortsatt en medicinsk utmaning i flera delar av världen. Sjukdomen drabbar ofta barn och behovet av effektiva läkemedel är stort eftersom malaria kan inducera en systemisk inflammatorisk reaktion som leder till multiorgansvikt, en reaktion som liknar den man ser vid sepsis/septisk chock. Syftet med det samarbete som annonseras idag är att genomföra en klinisk studie för a

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES15.6.2021 09:30:00 CEST | Press release

Bid date, 2021-06-15Auction date2021-06-15Settlement date2021-06-16Maturity Date2021-06-23Nominal amount484 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume484 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term968 billion SEKExpected excess liquidity at full allotment484 billion SEK Stockholm, 2021-06-15

Klövern kommer att sammankalla en extra bolagsstämma enligt begäran från Corem15.6.2021 09:06:03 CEST | Pressemelding

En extra bolagsstämma kommer att hållas i Klövern AB (publ) (”Klövern”) den 9 juli 2021 för val av ny styrelse i enlighet med begäran från Corem. Kallelse utfärdas separat. Corem Property Group AB (publ) (”Corem”) lämnade den 29 mars 2021 ett offentligt uppköpserbjudande till aktieägarna i Klövern. Corem förklarade idag erbjudandet ovillkorat och förlängde acceptfristen till den 23 juni 2021. Corem kontrollerar cirka 89,1 procent av de utestående aktierna och cirka 90,8 procent av rösterna i Klövern. Klövern AB (publ) För ytterligare information, vänligen kontakta: Pia Gideon, styrelseordförande i Klövern Tel: 070-546 71 00 Klövern är ett fastighetsbolag som med närhet och engagemang erbjuder attraktiva lokaler i tillväxtregioner. Klövern är noterat på Nasdaq Stockholm. Ytterligare information finns på www.klovern.se. Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Tel: 010-482 70 00, Email: info@klovern.se. Detta pressmeddelande har offentliggjorts på svenska och engelska. Vid en ev

Klövern will convene an Extraordinary General Meeting in accordance with a request from Corem15.6.2021 09:06:03 CEST | Press release

An Extraordinary General Meeting will be held in Klövern AB (publ) (”Klövern”) on 9 July 2021 to elect a new Board of Directors in accordance with a request from Corem. A notice will be issued separately. On 29 March 2021, Corem Property Group AB (publ) (”Corem”) announced a public offer to the shareholders of Klövern. Today, Corem declared the offer unconditional and extended the acceptance period to 23 June 2021. Corem controls approximately 89.1 percent of the outstanding shares and approximately 90.8 percent of the votes in Klövern. Klövern AB (publ) For further information, pleasecontact: Pia Gideon, Chairman of the Board of Directors in Klövern Phone: +46 70 546 71 00 Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se. Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Phone: +46 10 482 70 00. Email: info@klovern.se. This